Compare BRC & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRC | TGTX |
|---|---|---|
| Founded | 1914 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.9B |
| IPO Year | 2005 | 2008 |
| Metric | BRC | TGTX |
|---|---|---|
| Price | $82.12 | $33.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $1.20 | ★ $49.80 |
| AVG Volume (30 Days) | 220.6K | ★ 1.6M |
| Earning Date | 05-15-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | N/A | ★ 2.77 |
| Revenue | ★ $1,144,698,000.00 | $2,785,000.00 |
| Revenue This Year | $7.36 | $49.08 |
| Revenue Next Year | $3.57 | $26.69 |
| P/E Ratio | $23.35 | ★ $12.30 |
| Revenue Growth | ★ 5.86 | N/A |
| 52 Week Low | $65.76 | $25.37 |
| 52 Week High | $99.29 | $40.99 |
| Indicator | BRC | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.16 | 49.29 |
| Support Level | $76.10 | $32.95 |
| Resistance Level | $82.71 | $35.33 |
| Average True Range (ATR) | 2.45 | 1.28 |
| MACD | 0.03 | -0.43 |
| Stochastic Oscillator | 35.71 | 13.01 |
Brady Corp provides identification solutions and workplace safety products. The company offers identification and healthcare products that are sold under the Brady brand to maintenance, repair, and operations as well as original equipment manufacturing customers. Products include safety signs and labeling systems, material identification systems, wire identification, patient identification, and people identification. Brady also provides workplace safety and compliance products such as safety and compliance signs, asset tracking labels, and first-aid products. The company is organized and managed on a geographic basis with two reportable segments: Americas & Asia which derives maximum revenue, and Europe & Australia.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.